$EYPT
EyePoint Pharmaceuticals Inc
PRICE
$9.23 โฒ1.317%
Last Close
VOLUME
150,945
DAY RANGE
9 - 9.41
52 WEEK
7.3 - 21.5
Key Metrics
Market Cap
314.25 M
Beta
1.21
Avg. Volume
112.07 K
Shares Outstanding
34.05 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-03
Next Dividend Date
Company Information
EYP-1901 is a potential twice-yearly sustained delivery intravitreal anti-VEGF treatment for wet age-related macular degeneration. EYP-1901 leverages a bioerodible formulation of EyePoint's proprietary Durasertยฎ sustained release technology with vorolanib, a tyrosine kinase inhibitor. Vorolanib provided clear efficacy signals in two prior human trials in wet AMD as an orally delivered therapy with no significant ocular adverse events. EYP-1901 is currently in a Phase 1 clinical trial initially targeting treatment of wet AMD, with the potential for additional indications in diabetic retinopathy and retinal vein occlusion.
Website: eyepointpharma.com
HQ: ,
Related News